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Background: In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule
proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in
lymphoproliferative disorders as well as autoimmune diseases. However, the chronic nature of these diseases
requires either prolonged or re-treatment, often with acquired resistance as a consequence.
Methods: Here we studied the molecular basis of acquired resistance to BTZ in JY human B lymphoblastic cells
following prolonged exposure to this drug and examined possibilities to overcome resistance by next generation
PIs and anti-CD20/rituximab-mediated complement-dependent cytotoxicity (CDC).
Results: Characterization of BTZ-resistant JY/BTZ cells compared to parental JY/WT cells revealed the following
features: (a) 10–12 fold resistance to BTZ associated with the acquisition of a mutation in the PSMB5 gene
(encoding the constitutive β5 proteasome subunit) introducing an amino acid substitution (Met45Ile) in the
BTZ-binding pocket, (b) a significant 2–4 fold increase in the mRNA and protein levels of the constitutive β5
proteasome subunit along with unaltered immunoproteasome expression, (c) full sensitivity to the irreversible
epoxyketone-based PIs carfilzomib and (to a lesser extent) the immunoproteasome inhibitor ONX 0914. Finally, in
association with impaired ubiquitination and attenuated breakdown of CD20, JY/BTZ cells harbored a net 3-fold
increase in CD20 cell surface expression, which was functionally implicated in conferring a significantly increased
anti-CD20/rituximab-mediated CDC.
Conclusions: These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next
generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in
BTZ-resistant disease.
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Since the initial approval of rituximab, a monoclonal
antibody against CD20, in 1997, it has become the
cornerstone in the treatment of B cell lymphoprolifera-
tive diseases [1]. Additionally, B cells play a pivotal role
in the pathogenesis of inflammatory autoimmune disor-
ders such as rheumatoid arthritis (RA) and systemic
lupus erythematosus (SLE), for which reason over the
past decade rituximab has been added as B cell depleting
therapy of auto-immune diseases [2-6]. However, it is
well recognized that a considerable number of patients
are either primary resistant to rituximab, or experience a
limited period of response [5,7]. The efficacy of rituxi-
mab is associated with proficient CD20 expression on
the surface of B cells, and indeed, acquisition of rituxi-
mab resistance appears to be correlated with down-
regulation of CD20 [8,9]. Therefore, there is an urgent
need for new therapeutic modalities. Beyond immuno-
therapy approaches, small molecule targeting of B-cells
has been achieved with proteasome inhibitors (PIs) such
as bortezomib (BTZ) [10]. Bortezomib-induced apop-
tosis and cell death has been reported for a large panel
of human B cell lines, including those resistant to rituxi-
mab therapy [11-13]. Accordingly, a clinical effect of
BTZ in B cell driven diseases has been found. BTZ is
highly effective in inducing plasma cell death, thus, is
now being implemented both in first line and relapsed
and refractory multiple myeloma (MM) [14]. BTZ has
also shown clinical efficacy in Mantle Cell Lymphoma
[15] and Waldenström’s Macroglobulinemia [16], the lat-
ter also in combination with rituximab [17], indicating
its effectivity in inducing cell death in earlier stages of B-
cell development. In the autoimmune disease setting,
clinical studies with PIs are far less advanced, although
in pre-clinical studies, PI therapy demonstrated promis-
ing results as anti-arthritic treatment strategy, also by B
cell depletion [18-22].
One hypothesis for proficient B cell targeting by PIs is
that their substantial turnover and secretion of proteins
renders these cells highly susceptible to interference in
protein homeostasis, in particular following inhibition of
the ubiquitin proteasome system (UPS) [23]. The UPS is
the master regulator of cellular homeostasis by mediating
ubiquitination and degradation of proteins that control
apoptosis induction, and also mediate pro-inflammatory
cytokine production via NFκB activation [24-26]. Most
mammalian cells express constitutive proteasomes which
harbor the β5 subunit (PSMB5), the β1 subunit (PSMB6)
and the β2 subunit (PSMB7) and cleave proteins (or long
peptides) after hydrophobic, acidic, and basic amino acid
residues, respectively [27,28]. After stimulation with IFN-γ
and/or TNF-α, these constitutive proteasome subunits are
replaced by immunoproteasome subunits: β5i (LMP7), β1i
(LMP2), and β2i (MECL1) [29]. These proteasome entitiesare part of the immunoproteasome, which is mainly
expressed in cells of hematological origin and can gener-
ate a distinct peptide repertoire for MHC-class I presenta-
tion [30]. As a first generation PI, Bortezomib targets both
constitutive and/or immunoproteasome subunits via a re-
versible binding to the proteasome, however, nowadays
several next-generation PIs have been rationally designed
and tested, harboring the capacity to specifically target the
constitutive and/or immunoproteasome subunits through
irreversible binding [23,28,29,31-35].
Given the chronic nature of autoimmune-related dis-
eases, with patients facing long-term treatment, it is
anticipated that PI treatment may also be accompanied
by loss of treatment efficacy/onset of drug resistance
over time (Kumar et al., 2012), as has been described in
extensively-treated MM patients [36,37]. We, as well as
others, have described the development of resistance to
BTZ in several models of hematological cancer cells, in-
cluding T-cells, myeloid cells, and plasma cells [38-41].
For both benign and neoplastic B cells, however, the
long term effects of BTZ exposure are largely unex-
plored and deserve further investigation.
In this study, we investigated the long-term effects of B-
cell exposure to BTZ and onset of resistance to BTZ using
EBV-transformed JY lymphoblast cells as a benign auto-
immune disorder in vitro B-cell model. Beyond character-
izing the molecular basis of resistance to BTZ in JY cells,
we report two modalities to overcome BTZ resistance
in B cells; (a) by next-generation epoxyketone-based irre-
versible PIs, and (b) by enhanced rituximab-mediated
complement-dependent cytotoxicity (CDC), exploiting
the upregulated cell surface expression of CD20 in BTZ-
resistant JY cells.
Results
Acquisition of bortezomib resistance and cross-resistance
to other proteasome inhibitors
The human JY B cell line was used as a model to examine
the cellular effects of long-term exposure of B cells to
BTZ, including the acquisition of BTZ resistance. Cell cul-
tures were exposed to a low concentration of BTZ (IC10:
1.5 nM) which was gradually (stepwise) increased to 100
nM of BTZ over a period of 6 months. JY cells stably
growing in BTZ concentrations of 35nM (JY/35) and
100nM (JY/100) were used for further characterization.
Figure 1A shows the growth inhibition profiles of JY/
WT, JY/35 and JY/100 cells after 72 hrs treatment with
BTZ, revealing a clear shift in drug concentrations caus-
ing 50% cell growth inhibition (IC50 value) in JY/35 and
JY/100 cells. Figure 1B shows a 10-fold and 12-fold BTZ
resistance in JY/35 and JY/100 cells, respectively, com-
pared to JY/WT cells. Cross-resistance to other prote-
asome inhibitors (PI) was also determined in JY/35 and
JY/100 cells; a low level of cross-resistance was found
Figure 1 Acquisition of bortezomib (BTZ) resistant JY cells and proteasome inhibitor cross-resistance profile. (A) Dose–response curve
for BTZ-induced growth inhibition of JY/WT and BTZ-resistant variants JY/35BTZ and JY/100BTZ following 72 hours exposure to BTZ. Results
represent the mean ± SD of 6 separate experiments. (B) Resistance factor for BTZ and cross- resistance factors to ONX 0914 (immunoproteasome
inhibitor), MG-132, and carfilzomib. Cell growth inhibition was assessed after 72 hours incubation with PIs. (Cross) resistance factor represents the
ratio of drug concentration required to inhibit cell growth of BTZ-resistant JY cells by 50% over JY/WT cells. Results are the mean ± SD of 3–5
separate experiments.
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(resistance factor: 3.4 and 2.9, respectively) and the pan-
proteasome inhibitor MG-132 (resistance factor: 2.3 and
2.2, respectively). Remarkably, however, JY/35 and JY/
100 cells retained full sensitivity towards the next-
generation irreversible PI, carfilzomib.
Molecular alterations in BTZ-resistant JY cells
We and others [38-41] have previously discovered a
mechanism of BTZ resistance in various haematological
cell lines. This mechanism included BTZ-induced single
point mutations in the PSMB5 gene, as well as a selective
overexpression of mutant PSMB5 protein [38,39,41]. Here,
we tested whether this mechanism would also apply for
BTZ-resistant JY cells. We first determined whether
PSMB5 harbored any of the previously described muta-
tions [38-41]. Indeed, in JY/35 cells as well as JY/100 cells,
a single G to T nucleotide shift was identified at nucleo-
tide position 311 in exon 2 of the PSMB5 gene (Additional
file 1: Figure S1). In the mature and functional β5-subunit
protein, this mutation introduced a Met to Ile substitution
at amino acid 45. It is noteworthy that the mutation in
PSMB5 in JY/35 and JY/100 cells is heterozygous, indicat-
ing that these cells would still harbor one unaffected allele.
We next determined the expression of the constitutive
and immunoproteasome subunits at both mRNA and pro-
tein levels (Figure 2). Compared to JY/WT cells, mRNA
levels of the constitutive proteasome subunits, in particu-
lar PSMB5 (β5) and PSMB7 (β2), were significantly
increased (up to 4.5 fold) in JY/BTZ cells, whereas the in-
crease in the mRNA of immunoproteasome subunits was
much less pronounced (Figure 2A). Consistent with these
data, protein levels of constitutive proteasome subunits
were increased in BTZ-resistant JY cells (up to 2-fold),whereas the expression levels of immunoproteasome sub-
units remained largely unaltered (Figure 2B-D).
Surface molecules involved in antigen-presentation
JY cells are efficient antigen-presenting cells [42] and we
therefore examined whether or not BTZ selection would
induce alterations in markers involved in antigen presen-
tation. In fact, no significant changes were found in the
cell surface expression of HLA-ABC (MHC-class I),
HLA-DR (MHC-class II), and the co-stimulatory mole-
cules CD80, CD86, and CD40 in JY/35 and JY/100 cells
compared to JY/WT cells (Additional file 1: Figure S2).
Further confirmation that BTZ selection had no impact
on antigen presentation was provided by the observation
that JY/WT and BTZ-resistant cells showed no differ-
ence in their capacity to induce allogeneic T-cell prolif-
eration (Additional file 1: Figure S3). Of note, short term
(24 hr) incubations with maximal non-toxic concentra-
tions of BTZ also did not affect their ability to induce
proliferation of allo-T-cells (Additional file 1: Figure S3).
Cytokine release capacity by BTZ-resistant JY cells
Activated B cells are able to produce cytokines and conse-
quently contribute to inflammation [43] or protective
cytokine environments [44]. To this end, we examined the
secretion profile of the prototypical pro-inflammatory
cytokine TNF-α by activated JY cells and explored whether
or not this profile is altered in JY/BTZ cells. Beyond basal
secretion levels, we also assessed the impact of co-
incubation with BTZ on TNF-α production. Upon activa-
tion with PMA and ionomycin, JY cells produced TNF-α
levels of 7000 ± 3700 pg/ml, which was diminished by
20% in the presence of 10 nM BTZ (Figure 3). Basal levels
of TNF-α production in JY/35 cells was approximately
Figure 2 Constitutive and immunoproteasome composition in JY cells and BTZ-resistant variants. (A) Relative mRNA levels of constitutive
and immunoproteasome subunits in JY/WT and BTZ-resistant variants JY/35BTZ and JY/100BTZ. mRNA levels were normalized relative to
β-glucuronidase as house keeping gene. (B) Protein expression of constitutive and immunoproteasome subunits in JY/WT and BTZ-resistant
variants JY/35BTZ and JY/100BTZ. (C) Relative protein expression of constitutive and immunoproteasome subunits in JY/WT and BTZ-resistant
variants JY/35BTZ and JY/100BTZ. (D) Total constitutive and immunoproteasome subunit expression in JY/WT and BTZ-resistant variants
JY/35BTZ and JY/100BTZ. Results depicted are means ± SD of 3–5 separate experiments. *** p < 0.001, ** p < 0.01, * p < 0.05.
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the presence of 35 nM BTZ. Strikingly, basal TNF-α pro-
duction in JY/100 was markedly decreased to levels < 5%
of JY/WT cells. Together, these results indicate that upon
acquisition of BTZ resistance, JY cells are markedly sup-
pressed in their capacity to secrete TNF-α.
CD19 and CD20 expression in BTZ-resistant JY cells
CD19 and CD20 are prototypical B cell surface markers,
and lost upon differentiation to plasma cells [2,3,45]. We
examined whether or not induction of BTZ-resistance
altered CD19 and/or CD20 expression levels in JY/BTZ
cells. Flow cytometric analyses revealed a significant de-
crease in CD19+ cells (55 ± 16%) in JY/WT cells to 14 ±
11% in JY/100 cells (Figure 4A) along with a concomi-
tant 3-fold decrease in CD19 cell surface expression
(Figure 4B). Interestingly, CD20 expression profiling was
the inverse of CD19 in positive cells (Figure 4C),
whereas CD20 cell surface expression was 2.8-foldhigher in the resistant JY/100 cells than JY/WT cells
(Figure 4D).
Regulation of CD20 expression in BTZ-resistant JY cells
Recently, it has been reported [46] that proteasome
inhibition and ubiquitination of CD20 triggers its deg-
radation and decreases its cell surface expression. Con-
sistent with this notion, we observed that CD20
expression was significantly decreased on JY/WT cells
exposed for up to 48 hrs to 5 nM BTZ (Figure 5A). In
comparison, no effect of BTZ treatment was observed
for HLA-DR expression (Figure 5B). Unlike in JY/WT
cells, treatment of JY/35 and JY/100 cells with BTZ (35
nM and 100 nM BTZ, respectively) had no significant
effect on CD20 expression (Figure 5A). In order to es-
tablish whether protein ubiquitination status after short-
term (24–48 hr) BTZ treatment is associated with
down-regulation of CD20 expression in JY/WT cells and
unaltered CD20 expression in JY/BTZ cells, Western
JY
/ W
T
JY
/ W
T +
10
nM
BT
Z
JY
/35
JY
/ 3
5 +
35
nM
BT
Z
JY
/10
0
JY
/ 1
00
+
10
0n
M
BT
Z
0
50
100
100
200
300
400
1000
4000
7000
10000
CTR
PMA + Ionomycin
TN
F-
(pg
/m
l)
*
*
**
Figure 3 TNF-α release by JY/WT cells and BTZ-resistant variants JY/35BTZ and JY/100BTZ. Cells were activated for 24 hours with 10 ng/
ml PMA and 750 ng/ml Ionomycin, in the absence or presence of the indicated concentration bortezomib. Results depicted are means ± SD of 3
separate experiments. ** p < 0.01, * p < 0.05.
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formed with control and BTZ- exposed cells. Figure 5C
shows a typical smear of (poly) ubiquitinated proteins
when JY/WT cells were incubated with 10 nM BTZ for
24 hrs. Conversely, no accumulation of ubiquitinatedCD19 %
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Figure 4 Expression of B cell surface markers CD19 and CD20 on JY/WT
cells and BTZ-resistant variants. (B) Expression of CD19 in BTZ-resistant JY cells
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exposed to 35 nM and 100 nM BTZ, respectively. These
results suggest that aberrant protein ubiquitination and
degradation could be a contributing factor towards ele-
vated levels of CD20 in BTZ-resistant JY cells.CD20 expression
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Figure 5 Effect of BTZ on CD20 (A) and HLA-DR (B) expression in JY/WT and BTZ-resistant JY cells. Short term incubations of 24 hours
and 48 hours were performed with 5nM BTZ for JY/WT, 35nM for JY/35BTZ cells and 100nM BTZ for JY/100BTZ cells. Results depicted are means
± SD of 3–4 separate experiments. * p < 0.05. (C) Western blot analysis of polyubiquitinated cellular proteins prior to and after 24 hours
treatment of BTZ; JY/WT (± 10nM BTZ), JY/35 (± 35nM BTZ) and JY/100 (± 100nM BTZ). β-Actin is displayed as a loading control. Western blot
image is representative of 3 separate experiments.
Figure 6 Rituximab-induced CDC in JY/WT and BTZ-resistant
JY cells. Cells were incubated with increasing concentrations
anti-CD20/rituximab (range; 0.1 μg-50 μg/ml) and 5% baby
rabbit complement serum. Cell viability (% lysis) was measured
after 1 hour using propidium iodide (PI) staining and FACS
analysis. Results depicted are means ± SD of 5–8 separate
experiments. *** p < 0.001, ** p < 0.01.
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CDC in bortezomib-resistant JY cells
To explore whether or not increased expression levels
of CD20 in JY/100 cells is therapeutically relevant,
we investigated its impact on anti-CD20/rituximab-
induced complement-dependent cytotoxicity (CDC). In
the presence of 5% baby rabbit serum [47] and over a
broad range of rituximab concentrations, significantly
increased CDC was noted for JY/100 cells as com-
pared to JY/WT cells with a mean difference of 17%
lysis (Figure 6). This increase was not associated with
alterations in CD55 and/or CD59 expression levels be-
tween JY/WT and JY/BTZ cells, two markers impli-
cated in controlling CDC [9,46] (not shown). Together,
these results suggest that increased expression levels
of CD20 in JY/BTZ cells may be exploited as an alter-
native therapy to combat BTZ resistance through
rituximab-induced CDC.
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The current study describes two ways to overcome
acquired resistance to BTZ in JY human B cells: (a) anti-
CD20/rituximab-mediated CDC, and (b) next generation
epoxyketone-based irreversible PIs.
B cell depleting therapies utilizing the anti-CD20/rituxi-
mab antibody approach, as well as the small molecule
approach with the proteasome inhibitor BTZ, have demon-
strated clinical efficacy in the treatment of lymphoprolifera-
tive disorders [1,10,23,48]. In the treatment of autoimmune
diseases, rituximab also now has an accepted place [3-5,43],
but BTZ or other PIs still await clinical evaluation. Ideally,
based on their non-overlapping mechanisms of action,
rituximab and bortezomib could potentially replace each
other when development of resistance to one or the other
occurred. In this context, it has been reported that
rituximab-resistant B cells retain sensitivity for BTZ, but
the reverse has not been demonstrated. In view of the need
for chronic treatments in autoimmune diseases, there are
concerns about the emergence of resistance [36], thus high-
lighting the need to unravel underlying mechanisms of
resistance, in order to design strategies to overcome
acquired resistance. To address these issues, we provoked
acquired resistance to BTZ in a human B cell line model
and investigated its impact on rituximab sensitivity and
next-generation PIs designed to overcome BTZ-resistance.
Here we mimicked the onset of acquired BTZ resistance
in human B cells using human JY lymphoblastic cells as
benign autoimmune disorder in vitro model, by a classical
approach of cell exposure to stepwise increasing concen-
trations of BTZ (5 through 100 nM), representing
clinically-achievable plasma levels [10,23]. Characterization
of the BTZ-resistant JY cells (10–12 fold compared to WT
cells) revealed the following main features: 1) acquisition of
a point mutation in the PSMB5 gene (encoding for the
constitutive β5 proteasome subunit) along with overex-
pression of β5 subunit protein, 2) retention of sensitivity to
epoxyketone-based PIs including carfilzomib, 3) an altered
cytokine environment indicated by a marked reduction in
the secretion of the inflammatory cytokine TNF-α, and 4)
immunophenotypically, a significantly reduced expression
of the B cell surface marker CD19 and a concomitant in-
crease in CD20 levels.
BTZ-resistance associated with a single point mutation
in PSMB5 has been demonstrated by us and others for
leukemia cell lines of lymphoid and myeloid origins, as
well as solid tumor cell lines [38-41,49]. These mutations
introduced amino acid alterations that clustered in crit-
ical positions (Thr21, Met45, Ala49 and Cys52) in the
BTZ binding pocket within the β5 subunit [41]. Based
on data from the present study, it is revealing that be-
yond hematological malignant cells, PSMB5 mutations
can also be identified in BTZ-resistant JY lymphoblastic
cells. It is noteworthy that the mutation in PSMB5 inJY/BTZ cells is heterozygous, indicating that cells still
retained an intact WTallele. This may underlie a relatively
lower level of BTZ resistance observed in JY/BTZ cells
as compared to the substantially higher resistance levels
(> 100-fold) noted in leukemic cells harboring homozy-
gous mutations in PSMB5 [38,41]. Notwithstanding this
fact, expression levels of mutant β5 subunits were upregu-
lated in JY/BTZ cells, likely as a compensatory mechanism
to sustain basal proteasome activity. The Met45Ile substi-
tution identified in BTZ-resistant JY cells consistently
resided in the highly-conserved substrate/inhibitor-bind-
ing domain of the β5 subunit. Met45 is well recognized to
be essential for proteasome-substrate interactions, as well
as for binding of the leucine boronic acid moiety (P1 site)
of BTZ [29,32,50]. In this context, it may be anticipated
that replacement of the non-polar, spatially flexible Met45
for another slightly more non-polar, bulkier, and more
rigid amino acid as Ile, would affect optimal BTZ binding,
thereby resulting in the conferring of drug resistance.
From this perspective, it is intriguing to note that the
Ala49 and Met45 mutations in the β5 subunit were also
identified in marine bacteria as a self-protection mechan-
ism against the natural PI, salinosporamide A, that they
produce [51].
A major finding in the current study is that JY/BTZ cells
harboring the Met45Ile mutation in the β5 subunit
retained full sensitivity to carfilzomib, an epoxyketone-
based PI. Previous studies from our laboratory also indi-
cated that carfilzomib retained appreciable activity against
BTZ-resistant leukemia [41,52] and solid tumor cell lines
[23,35,49]; similar findings were observed with ONX 0912
[53], an orally- bioavailable analog of carfilzomib which
provokes irreversible binding via the epoxyketone group to
the active site Thr1 residue in the β5 subunit. This unique
property, rather than reversible binding by boronate-based
BTZ, may still facilitate inhibition of the catalytic activity in
mutated β5, thereby resulting in retention of drug sensitiv-
ity. Since levels of immunoproteasome subunits were
largely unaltered and no mutations were observed in the
β5i subunit in JY/BTZ cells, it may also explain the mar-
ginal levels of cross-resistance that were observed for the
immunoproteasome-specific inhibitor ONX 0914. In this
context, it is worthwhile mentioning that recent crystal
structure studies identified Met45 in β5i as a major deter-
minant in the efficient docking of ONX 0914 to the cata-
lytic binding site [29]. The Met45Ile mutation in the
constitutive β5 subunit has apparently lesser consequences
for ONX 0914 activity [20]. Together, constitutive and
immunoproteasome targeted epoxyketone-based PIs like
carfilzomib, currently evaluated in phase I-III clinical
trials [54], as well as ONX 0914 may readily overcome
BTZ-resistance.
Besides antiproliferative effects, BTZ can also elicit po-
tential anti-inflammatory effects by suppression of the
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of NF-κB activation [18-20,25,26]. In this respect, TNF-α
has received the most attention as one of the critical
cytokines in the pathophysiology of arthritis, and is thus
a major druggable target for biological agents and small
molecules [20-22,48]. Consistent with data from the
Komano group [55], we noted that JY/WT cells could
produce appreciable levels of TNF-α, which could be
partially inhibited by BTZ. Of additional interest was the
notion that alongside these short term effects, acquisi-
tion of BTZ resistance in JY cells provoked a dramatic
reduction in the basal levels of TNF-α production, being
most pronounced in JY/100 cells. It remains to be estab-
lished whether or not this effect is due to diminished re-
sponse to activation stimuli, or aberrations in TNF-α
secretion per se. In either case, prolonged BTZ exposure
may elicit potential anti-inflammatory effects even when
anti-proliferative effects are compromised.
Acquisition of BTZ resistance in JY cells was associated
with opposite impacts on cell surface expression of two
common B-cell surface markers: down regulation of CD19
and upregulation of CD20. CD19 is a transmembrane pro-
tein and co-receptor molecule that modulates signals
through the B cell antigen receptor (BCR) to control B
cell-differentiation from pro/pre-B cells to resting pre-B
cells in bone marrow. Consistently, CD19−/− mice have
exhibited defects at stages of early B cell development
and reduced levels of circulating B-cells, as reviewed in
Del Nagro et al. [45]. It is yet unclear whether reduced
CD19 levels in JY/BTZ cells would result in a B cell dif-
ferentiation arrest; this should be subject for further
studies using panels of B cell differentiation-restricted
cell surface markers.
CD20 serves as a Ca2+-permeable cation channel pro-
tein expressed on B cells from immature to mature
stages of differentiation, as recently reviewed by Thaunat
et al. [2]. BTZ has been reported to induce disregulation
of intracellular Ca2+, triggering caspase activation and
initiating apoptosis [56]. It is unknown whether this off-
target effect of BTZ alters CD20 function and expression
during resistance development. Rather, recent studies
have pointed to the role of the ubiquitin proteasome sys-
tem in the regulation of CD20 expression, as rituximab-
resistant lymphoma cells have displayed upregulated
expression of proteasome subunits [8], and treating Raji
human Burkitt lymphoma cells with BTZ for 24–
48 hours has down-regulated CD20 expression [46]. In
accordance with these studies, we now showed that
impaired (poly) ubiquitination of proteins upon 24–
48 hour BTZ treatment in resistant JY/BTZ cells attenu-
ated degradation of CD20, resulting in a net 3-fold
increase in CD20 expression in JY/100 cells and mark-
edly enhanced rituximab-mediated CDC in JY/100 cells
as compared to JY/WT cells. Based on the differentialimpact on CD20 expression in BTZ-sensitive and BTZ-
resistant cells, one should take caution when considering
combining rituximab and BTZ for B cell targeting; effi-
cacy may only be realized in BTZ-resistant cells. More-
over, the current findings for JY lymphoblastic cells
should also await further corroboration for B-cell neo-
plasms (e.g. mantle cell lymphoma) for which BTZ is a
therapeutic option. Finally, it would be of additional fu-
ture interest to explore whether aberrations in protein
ubiquitination provoked by prolonged exposure to either
BTZ or other types of PIs, may be instrumental to upre-
gulated expression of other B cell surface markers that
could elicit antibody-mediated CDC.
Conclusions
In conclusion, this study presented two novel strategies to
overcome acquired resistance to BTZ in human B
lymphoblastic cells: one is a small molecule approach with
irreversible epoxyketone-based PIs, whereas the second
relates to an immunological approach by anti-CD20/ritux-
imab-mediated CDC, exploiting the upregulation of CD20
in BTZ-resistant cells. This deserves further exploration in
order to improve the clinical outcome in patients with
bortezomib-resistant diseases.
Methods
Cell culture and development of BTZ-resistant cell lines
The human EBV-transformed B-lymphoblastic cell line JY
(ATCC) was cultured in IMDM-medium (PAA, The Cell
Culture Company, PAA Laboratories GmbH, Germany)
supplemented with 10% FCS, 1% β-mercaptoethanol, 1%
penicillin, 1% streptomycin and 2 mM L-glutamine. BTZ-
resistant JY cell lines were established by stepwise increas-
ing concentrations of BTZ over a period of 6 months,
starting at a BTZ concentration of 1.5 nM (IC10 concen-
tration; establishing 10% cell growth inhibition compared
to the untreated control) up to a concentration of 100
nM. Cells stably growing in the presence of 35 nM (JY/35)
and 100 nM BTZ (JY/100) were isolated after 3 months
and 6 months of stepwise selection, respectively. Unless
otherwise indicated, experiments were performed with
cells cultured in drug-free medium for at least 4 days.
Reagents / chemicals / antibodies
Bortezomib (BTZ)/Velcade™ was provided by Millen-
nium Pharmaceuticals (Cambridge, USA). Carfilzomib
and ONX 0914 were generously provided by Onyx Phar-
maceuticals, Inc. (South San Francisco, USA). MG132
(Z-Leu-Leu-Leucinal) was purchased from Calbiochem/
Merck (Nottingham, UK). Phorbol-12-myristate 13-
acetate (PMA) and ionomycin were from Sigma (St.
Louis, MO, USA).
Rituximab, a chimeric immunoglobulin G1, was pur-
chased from Roche (Roche Netherlands B.V., Woerden,
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lowing sources: ubiquitin: (P4D1, Santa Cruz Biotech-
nology, sc-8017) and β-actin (C4, Santa Cruz, sc-47778)
mouse monoclonal antibodies; goat-anti-mouse second-
ary antibody conjugated to IRDyeW 800CW (Odyssey;
L1-COR Biosciences, Nebraska, USA).
Isolation of mRNA, cDNA synthesis, and quantitative
RT-PCR
Following RNA isolation with the RNeasy Mini kit
(Qiagen), cDNA was synthesized using 0.75U/ul M-MLV
reverse transcriptase (Invitrogen) in a RT buffer (Invitro-
gen), containing 5 mM DTT (Invitrogen), 2 mM dNTP
(Roche), pdN6 96ug/ml (Roche), and 2U/ulRNAsin (HT
Biotechnology Ltd., Cambridge, UK). mRNA expression
levels of proteasome subunits PSMB5 (β5), PSMB6 (β1),
PSMB7 (β2), PSMB8 (ß5i), PSMB9 (ß1i), PSMB10 (ß2i),
and the endogenous housekeeping gene β-glucuronidase
(GUS) as a reference, were quantified using real-time PCR
analysis (Taqman) using an ABI Prism 7700 sequence de-
tection system (PE Applied Biosystems, Nieuwerkerk a/d
IJssel, The Netherlands) as described previously [41].
Briefly, for PSMB5, a Taqman gene expression assay was
used according to the manufacturers’ instructions
(Hs00605652_m1, Applied Biosystems). All other primers
and probes were designed using Primer Express software
(Applied Biosystems) and are indicated in Additional file 1:
Table S1. Probes were labeled with 5’-FAM and 3’-BHQ1
as a reporter. Real-time PCR was performed in a total
reaction volume of 25 μl containing TaqMan buffer A
(Applied Biosystems), 4 mM MgCl2, 0.25 mM of each
dNTP (Amersham Pharmacia Biotech), and 1.25 U Ampli-
Taq Gold DNA polymerase (Applied Biosystems). Samples
were heated for 10 min at 95°C to activate the AmpliTaq
Gold DNA polymerase and amplified during 40 cycles of
15 s at 95°C and 60 s at 60°C. Relative mRNA expression
levels of the target genes in each sample were calculated
using the comparative cycle time (Ct) method. The Ct of
the target gene was normalized to the GUS Ct value by
subtracting the GUS Ct value from the target Ct value.
The mRNA expression level for each target PCR relative to
GUS was calculated using the following equation: mRNA
expression = 2(Ct target-Ct GUS) × 100%.
Proteasome constitutive-immuno subunit ELISA assay
(ProCISE)
The ProCISE assay for quantification of individual con-
stitutive (β5, β1, β2) and immunoproteasome (β5i, β1i,
β2i) subunits was performed as previously described
[33,34]. Expression of each c20S and i20S subunit in JY/
WT, JY/35, and JY/100 cells was examined after cells
were cultured in the absence of BTZ for one week. Pel-
lets of 10 x 106 -15 x 106 cells were washed three times
with PBS, frozen on dry ice, thawed, then incubated in100 μL of lysis buffer (20 mM Tris–HCl, pH 8.0, 5 mM
EDTA) for 15 minutes on ice. Lysed pellets were micro-
centrifuged (15 min, 14,000 rpm, 4°C), the supernatant
collected, and protein content determined by BCA assay
(Pierce), utilizing a BSA standard. Cell lysates were diluted
in lysis buffer to 1 mg/mL, and then incubated with a pro-
teasome active site probe (PABP; 5 μM) for 2 hours at
25°C. Samples were denatured with 8 M guanidine hydro-
chloride (Fisher Scientific) and subunits bound to PABP
were captured with streptavidin-conjugated sepharose
beads (GE Healthcare) in 96-well 0.65 μm porous filter
plates (Millipore). Individual subunits were probed with
subunit-specific primary antibodies, followed by secondary
antibodies conjugated to horseradish peroxidase (HRP).
The SuperSignal ELISA Pico chemiluminescent substrate
kit (Pierce) was utilized to generate luminescent signal
associated with HRP binding. Luminescence after 5 min-
utes of signal development was monitored on a plate
reader (Tecan Safire). Subunit content was expressed as
nanograms of subunit per microgram of total protein, as
calculated from a standard curve of human purified con-
stitutive or immunoproteasome, assayed simultaneously
with the cell lysate samples.
Cytokine release assay
JY cells were seeded in 96-wells plates at a cell density of 5
x 104/200μl and stimulated with 10 ng/ml PMA (Sigma)
and 750 ng/ml ionomycin (Sigma). After 24 hours, culture
supernatants were collected and analyzed using the cyto-
metric bead array (CBA) human inflammatory cytokines kit
(BD Biosciences, San Jose, CA) according to the manufac-
turer’s protocol. Quantitative measurements of TNF-α were
performed using a FACSCalibur flow cytometer (Becton
and Dickinson, San Jose, CA) with the CellQuest program.
FACS analysis – immunophenotyping
JY cells were immunophenotyped using FITC-, PE- and/or
APC-conjugated monoclonal antibodies (Mabs) directed
against: CD80 (1:10), CD86 (1:10), CD40 (1:10) HLA-ABC
(1:25), HLA-DR (1:25), CD19 (1:10), and CD20 (1:10) (BD
Biosciences, San Jose, CA) and CD54 (1:10) (Leinco Tech-
nologies Inc., St. Louis, USA). In short, 3 x 104 – 8 x 104
cells were washed with PBS supplemented with 0.1% BSA
and 0.02% NaN3, and incubated with specific or corre-
sponding isotype-matched control Mabs for 30 minutes at
4°C. Cells were washed and analyzed with a FACSCalibur
flow cytometer (Becton and Dickinson, San Jose, CA) using
the Cell Quest program. Results were expressed as percen-
tages of positive cells and the mean fluorescence index was
calculated based on mean fluorescence intensities.
Western blot analysis
Accumulation of ubiquitinated proteins upon treatment
with BTZ was determined by Western blot analysis as
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35 and JY/100 cells were incubated in 10 ml growth
medium in the absence or presence of 10nM, 35nM and
100nM BTZ, respectively. After 24 hours of incubation,
cells were harvested and washed 3 times with ice-cold
PBS at pH 7.4. Total cell lysates were prepared by resus-
pending in 0.1 ml lysis buffer (Cell Signaling Technology)
containing: 20% PIC (Protease Inhibitor Cocktail) and
10% NaVO4. The suspension was sonicated (MSE sonica-
tor, amplitude 7, for 3 × 5 seconds with 20-second
time intervals at 4°C) and centrifuged in an Eppendorf
micro-centrifuge (5 min, 12,000 rpm, 4°C). Protein con-
tent of the supernatant was determined by the Bio-Rad
Protein Assay using a bovine serum albumin (BSA) stand-
ard. Protein aliquots (30 μg) of total cell lysates were
fractionated on a 4-20% TGX pre-cast gel (BioRad) con-
taining SDS, and transferred onto a PVDF membrane.
The membranes were pre-incubated for 1 hour in block-
ing buffer (Rockland Immunochemicals Inc., Gilbertsville,
PA, USA) to prevent non-specific antibody binding. After
blocking, the membranes were incubated for 1 hour at
room temperature with an ubiquitin-specific antibody
(1:200). After 3 washing steps with Tris-buffered saline
with 0.5% Tween, the membranes were incubated for
1 hour with goat-anti-mouse secondary antibody conju-
gated to IRDye W 800CW (1:10000, Odyssey; L1-COR-
Biosciences, Nebraska, USA). Detection of antibody
binding was obtained using the LI-COR Odyssey scanner
(Biosciences) according to the manufacturers’ instructions,
and digital image acquisition and quantification was per-
formed using the Odyssey infrared imaging system soft-
ware (version 3.0.16, LI-COR Biosciences, Nebraska,
USA). Expression of ubiquitinated proteins was detected
using a mouse monoclonal antibody (1:200) as described
above. β-actin (1:1000 diluted antibody) was used as the
control for equal loading.
Complement-dependent cytotoxicity (R-CDC) assay
JY cells (5 x 104cells) were plated in triplicate in 96-well
plates in IMDM medium with or without rituximab
(concentrations ranging from 0.1 μg-50 μg/ml) and 5%
baby rabbit complement serum (Cedarlane, Ontario,
Canada). After 1 hour of incubation at 37°C, the num-
bers of non-viable cells were determined after propidium
iodide (PI) staining using flow cytometry. The percent-
age of lysed (PI+) cells was calculated based on a total of
1.2 x 104 measured events. Cell lysis in control condi-
tions (without baby rabbit serum) was subtracted to ob-
tain specific complement-dependent lysis.
Statistical analysis
For comparisons between groups, ANOVA and Student’s
t-test were used. Differences were considered to be sig-
nificant at p < 0.05.Additional file
Additional file 1: Table S1. Overview of primer and probe sequences
for PSMB6, PSMB7, PSMB8, PSMB9, PSMB10 and GUS. Primer design by
Vector NTI (Invitrogen) software. Additional file 1: Figure S1. Analysis of
PSMB5 gene mutations in BTZ-resistant JY cells. Sequencing of PSMB5
gene exon 2 in JY/WT cells and in the BTZ-resistant JY cells: JY/35BTZ
and JY/100BTZ. Depicted is the single nucleotide shift (G→T) at
nucleotide position 311 in JY/35BTZ and JY/100BTZ along with the
corresponding change in a single amino acid substitution (Met45Ile)
within the mature PSMB5/β5 protein JY wt: no mutation, JY/35: Met45Ile,
JY/100: Met45Ile. Additional file 1: Figure S2. Expression of markers
involved in antigen presentation in JY/WT and BTZ-resistant sublines. (A)
HLA-ABC (MHC-I) expression, (B) HLA-DR (MHC-II) expression, (C) CD80
expression, (D) CD86 expression, and (E) CD40 expression in JY/WT cells
and BTZ-resistant JY cells analyzed by FACS. Results depicted are
depicted as MFI over isotype control and represent the mean ± SD of 7-
9 separate experiments. Additional file 1: Figure S3. Induction of
allogeneic T-cell proliferation by JY/WT and BTZ-resistant JY cells. T cell
stimulatory capacity of the short term treatment (24 hours) of BTZ JY/WT
(± 10nM BTZ), JY/35 (± 35nM BTZ) and JY/100 (± 100nM BTZ). Results
depicted are means ± SD of 4 separate experiments.
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